Cardinal Health Inc vs GE Aerospace — how do they compare? Cardinal Health Inc trades at $234.16 (market cap $55.88B), while GE Aerospace trades at $368.1 (market cap $381.89B). The key difference: GE Aerospace is far larger — about 6.8× Cardinal Health Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| CAH | GE | |
|---|---|---|
Market Cap | $55.88B | $381.89B |
Sector | Health | Industrials |
52-Week High | $240.26 | $381.22 |
52-Week Low | $146.04 | $265.93 |
Enterprise Value | $59.91B | $391.70B |
Dividend Yield | 0.86% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
GE Aerospace trades at $366.70, down 0.91% with bullish technical momentum and strong fundamental performance. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $2.02 exceeding expectations of $1.86. Revenue growth accelerated to $45.86 billion in 2025 with net income margin improving to 17.72%. Analyst consensus remains strongly positive with 24 buy ratings and a $414.11 price target, representing 13% upside potential.
The outlook remains favorable with strong aerospace demand, defense contract wins, and expanding order backlog driving growth. Key risks include elevated valuation multiples (P/E 43.4, P/S 7.68) and potential execution challenges amid heavy investment in MRO and manufacturing expansion. The company's improving cash flow generation and strategic positioning in commercial engines and defense sectors support continued upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →